**Core Concept**
Diabetic macular edema (DME) is a complication of diabetes mellitus characterized by fluid accumulation in the macula, leading to vision impairment. Managing DME requires careful consideration of the underlying conditions, such as glaucoma, to prevent further complications. In this context, the choice of medication is crucial to avoid exacerbating either condition.

**Why the Correct Answer is Right**
The patient's glaucoma and DME necessitate the use of a medication that can address both conditions without worsening either. **Timolol**, a non-selective beta-blocker, is often used in glaucoma management to reduce intraocular pressure (IOP). However, beta-blockers can also decrease the production of aqueous humor, which may worsen DME. Nevertheless, the risk of worsening DME with timolol is lower than that of other options, making it a safer choice. In contrast, other medications like **latanoprost** (a prostaglandin analog) and **brinzolamide** (a carbonic anhydrase inhibitor) may worsen DME by increasing the production of aqueous humor.

**Why Each Wrong Option is Incorrect**
**Option A:** **Latanoprost** is a prostaglandin analog that increases the outflow of aqueous humor, which may worsen DME by reducing the clearance of fluid from the macula.
**Option B:** **Brinzolamide** is a carbonic anhydrase inhibitor that increases the outflow of aqueous humor, which may worsen DME by reducing the clearance of fluid from the macula.
**Option C:** **Pilocarpine** is a muscarinic receptor agonist that increases the outflow of aqueous humor, which may worsen DME by reducing the clearance of fluid from the macula.

**Clinical Pearl / High-Yield Fact**
When managing patients with DME and glaucoma, it's essential to weigh the benefits and risks of each medication and consider the potential impact on both conditions. The choice of medication may require a multidisciplinary approach, involving ophthalmologists, endocrinologists, and other specialists.

**Correct Answer: A. Timolol**